- Home
- FCBC vs ATXS Comparison
FCBC vs ATXS Comparison
Compare FCBC & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCBC | ATXS |
|---|---|---|
| Founded | 1874 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 612.1M | 732.4M |
| IPO Year | 1992 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FCBC | ATXS |
|---|---|---|
| Price | $34.83 | $12.49 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $24.33 |
| AVG Volume (30 Days) | 49.5K | ★ 786.8K |
| Earning Date | 01-23-2026 | 03-10-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.68 | N/A |
| Revenue | ★ $164,262,000.00 | $706,000.00 |
| Revenue This Year | $3.97 | N/A |
| Revenue Next Year | $9.85 | N/A |
| P/E Ratio | $12.91 | ★ N/A |
| Revenue Growth | ★ 0.67 | N/A |
| 52 Week Low | $31.21 | $3.56 |
| 52 Week High | $45.57 | $13.29 |
Technical Indicators
Market Signals| Indicator | FCBC | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 42.24 |
| Support Level | $32.50 | $12.49 |
| Resistance Level | $33.86 | $12.86 |
| Average True Range (ATR) | 0.87 | 0.24 |
| MACD | 0.11 | -0.07 |
| Stochastic Oscillator | 88.00 | 6.29 |
Price Performance
Historical ComparisonAbout FCBC First Community Bankshares Inc. (VA)
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.